From what 27 stock analysts predict, the share price for Abbott Laboratories (ABT) might increase by 12.44% in the next year. This is based on a 12-month average estimation for ABT. Price targets go from $104 to $149. The majority of stock analysts believe ABT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 27 Wall Street analysts have assigned ABT 21 buy ratings, 5 hold ratings, and 1 sell ratings. This means that analysts expect Abbott Laboratories to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ABT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ABT.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Matt Miksic Barclays | Overweight | $149 | Maintains | Nov 5, 2024 |
Adam Maeder Piper Sandler | Overweight | $133 | Maintains | Oct 17, 2024 |
Anthony Petrone Mizuho | Neutral | $130 | Maintains | Oct 17, 2024 |
Lee Hambright Bernstein | Outperform | $138 | Maintains | Oct 17, 2024 |
David Lewis Morgan Stanley | Equal-Weight | $117 | Maintains | Oct 17, 2024 |
Matthew Taylor Jefferies | Hold | $125 | Maintains | Oct 17, 2024 |
Danielle Antalffy UBS | Buy | $146 | Maintains | Oct 17, 2024 |
Jayson Bedford Raymond James | Outperform | $129 | Maintains | Oct 14, 2024 |
Suraj Kalia Oppenheimer | Outperform | $130 | Initiates | Oct 8, 2024 |
Shagun Singh RBC Capital | Outperform | $130 | Maintains | Oct 8, 2024 |
Vijay Kumar Evercore ISI Group | Outperform | $124 | Maintains | Oct 1, 2024 |
Raj Denhoy Jefferies | Hold | $120 | Reiterates | Sep 26, 2024 |
Adam Maeder Piper Sandler | Overweight | $131 | Initiates | Sep 19, 2024 |
Jefferies | Buy | Maintains | Aug 27, 2024 | |
Joanna Wiensch Citigroup | Buy | $127 | Maintains | Aug 22, 2024 |
Matt Miksic Barclays | Overweight | $143 | Maintains | Jul 29, 2024 |
Vijay Kumar Evercore ISI Group | Outperform | $120 | Maintains | Jul 2, 2024 |
Shagun Singh RBC Capital | Outperform | $125 | Reiterates | Jun 4, 2024 |
David Roman Goldman Sachs | Buy | $121 | Initiates | May 30, 2024 |
Joanna Wiensch Citigroup | Buy | $119 | Maintains | May 22, 2024 |
When did it IPO
1983
Staff Count
114,000
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Robert B. Ford
Market Cap
$199.29B
In 2023, ABT generated $40.11B in revenue, which was a decrease of -8.12% from the previous year. This can be seen as a signal that ABT's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Nearly 20,000 participants donated blood in the Abbott-Big Ten competition, potentially saving 60,000 lives. Nebraska won and received $1M from Abbott for health initiatives.
Why It Matters - The Abbott-Big Ten blood donation initiative enhances Abbott's brand visibility and community engagement, potentially boosting its stock performance and investor confidence in corporate social responsibility.
Summary - Abbott (ABT) is currently attracting attention from Zacks.com users, indicating potential interest and factors influencing the stock's future performance.
Why It Matters - Increased attention from Zacks.com users may indicate heightened interest or volatility in Abbott's stock, potentially influencing its price movements and investment decisions.
Summary - Analyst recommendations from brokerage firms influence stock prices, prompting investors to consider these ratings when deciding to buy, sell, or hold stocks.
Why It Matters - Analyst recommendations can significantly sway stock prices, impacting investor sentiment and trading decisions, which in turn affects market volatility and potential returns.
Summary - Abbott (ABT) closed at $115.59, down 0.33% from the previous trading session.
Why It Matters - Abbott's slight decline indicates potential volatility, signaling a need for investors to monitor market sentiment and performance trends closely.
Summary - Abbott is positioned to expand a capital-efficient licensing model, potentially increasing access to essential medicines for emerging market populations.
Why It Matters - Abbott's capital-efficient licensing model can expand market reach and revenue potential in emerging markets, enhancing its growth prospects and long-term shareholder value.
Summary - Abbott (ABT) closed at $118.77, reflecting a decrease of 0.15% from the previous trading day.
Why It Matters - Abbott's slight decline in stock price reflects market sentiment and potential concerns, influencing investor perceptions and future trading strategies.